Homayounfar, Kia

[["dc.bibliographiccitation.artnumber","570"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Schwoerer, Harald"],["dc.contributor.author","Vieth, Michael"],["dc.contributor.author","Veits, Lothar"],["dc.date.accessioned","2018-11-07T09:02:24Z"],["dc.date.available","2018-11-07T09:02:24Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Pyloric gland adenoma consists of closely packed pyloric-type glands lined by mucus-secreting cells. To date, approximately 230 cases have been reported, mostly of gastric localization with a tumour size up to 3.5 cm and a mean age of occurrence around 70 years. Adenocarcinoma develops in about 40% of cases and may be difficult to detect due to relatively mild nuclear atypia. Case presentation: We present the first case of a pyloric gland adenoma of the cystic duct in a 62-year-old male patient and demonstrate the clinicopathologic characteristics, including radiographic, molecular, and cytogenetic findings. The 2 cm-tumour developed in the cystic duct and protruded into the hepatic and common bile duct. On microscopic examination, it displayed closely packed pyloric-type glands, and focal architectural distortion with mild nuclear atypia. Immunohistochemically, it expressed MUC1, MUC5AC, MUC6 and p53, but not MUC2 and CD10. The Ki67-proliferation index was 25%. Furthermore, high-grade intraepithelial neoplasia was observed in the surrounding bile duct. We detected chromosomal gains at 7p, 7q11q21, 15q, 16p, 20, losses at 6p23pter, 6q, 18, and amplifications at 1q and 6p21p22 in the pyloric gland adenoma by comparative genomic hybridization. A KRAS codon 12 mutation (c.35G>T; p.G12V) was detected in the pyloric gland adenoma and in the adjacent dysplasia by sequencing analysis. The diagnosis of pyloric gland adenoma was established with transition into well-differentiated adenocarcinoma and high-grade biliary intraepithelial neoplasia. Conclusion: Pyloric gland adenoma evolving in the cystic duct is a rare differential diagnosis of obstructive bile duct tumours. Other premalignant bile duct lesions may be associated. Due to the risk of developing adenocarcinoma, surgical resection should be performed."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/1471-2407-12-570"],["dc.identifier.isi","000312906800001"],["dc.identifier.pmid","23206236"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8465"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24676"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2407"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Pyloric gland adenoma of the cystic duct with malignant transformation: report of a case with a review of the literature"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","633"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Langenbeck s Archives of Surgery"],["dc.bibliographiccitation.lastpage","641"],["dc.bibliographiccitation.volume","395"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T08:40:58Z"],["dc.date.available","2018-11-07T08:40:58Z"],["dc.date.issued","2010"],["dc.description.abstract","We evaluated individualized multimodal oncological strategies in patients with bilobular colorectal liver metastases (biCRC-LM) as well as their effect on R0 resection rates, disease-free survival (DFS), and overall survival (OS). Between January 2001 and December 2008, 64 patients were assigned to straightforward or two-stage liver resection +/- preoperative 5-fluorouracil (5FU)-based chemotherapy (CTx). Postoperative strategy after R0-resection was either \"wait and see\" or \"adjuvant\" therapy (3 cycles of CTx or anti-carcinoembryonic antigen (CEA)-radioimmunotherapy with (131)I-labetuzumab in a dose of 40-50 mCi/m(2)). Forty-three initially unresectable patients received preoperative CTx for downsizing of their biCRC-LM. Straightforward or two-stage liver resection was intended in 40 and 24 patients, respectively. Histopathologically confirmed R0-liver resection could be achieved in 47 patients. Surgical morbidity and mortality rates were 33% and 1.5%, respectively. Postoperatively, 26 patients received anti-cancer therapy (5 x CTx, 21 x anti-CEA-radioimmunotherapy). After R0-liver resection, median OS was significantly better compared to R1/R2 resections followed by palliative 5FU-CTx (38 versus 19 months, p = 0.035). There was no significant difference in DFS (p = 0.650) and OS (p = 0.435) between straightforward and two-stage liver resection. Compared to \"wait and see\" strategy, the application of postoperative therapy in adjuvant intent was associated with a better OS (p = 0.048). Extensive liver resection within multimodal treatment concepts is justified in patients with biCRC-LM when complete resection of all metastases seems to be achievable."],["dc.identifier.doi","10.1007/s00423-010-0604-7"],["dc.identifier.isi","000280241200005"],["dc.identifier.pmid","20213463"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4991"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19362"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1435-2443"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Multimodal treatment options for bilobar colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1463"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1469"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Lowes, Markus"],["dc.contributor.author","Kleiss, Mathias"],["dc.contributor.author","Lueck, Rainer"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","König, Alexander Otto"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Stanek, Kathrin"],["dc.contributor.author","Langer, Claus"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Homayounfar, Kia"],["dc.date.accessioned","2019-07-09T11:44:24Z"],["dc.date.available","2019-07-09T11:44:24Z"],["dc.date.issued","2017"],["dc.description.abstract","PURPOSE: Multidisciplinary tumor boards (MDT) have been advocated as standard of care in modern oncology. German guidelines for metastasized colorectal cancer (mCRC) recommend MDT discussion of colon cancer patients after completion of primary tumor therapy but stage IV colon cancer as well as rectal cancer patients prior to any therapy. In this health care research study, we evaluated application and decisional consequences of this approach in clinical routine. METHODS: All major institutions providing oncological care in southern Lower Saxony and Northern Hesse (N = 11) were invited. Patients with mCRC diagnosed between 01/2011 and 12/2013 were eligible. Data were collected using a standardized patient report form and stored in a GCP-conform EDC-system (secuTrial®). RESULTS: A university medical center, four teaching hospitals, one communal hospital, and three oncological focus practices participated in the study. In total, 470 patients with a median age of 70 years were enrolled. Guideline conform MDT discussion was performed in 63% of operated colon cancer patients, 38% of stage IV colon cancer patients and 47% of rectal cancer patients, respectively. Resection of metastases was performed in 41% of cases. Patients ≥70 years (n = 250) received significantly more often treatment following MDT discussion (86 versus 64%, p = 0.0002). Not the resection rate (48 versus 57%, p = 0.1574) but indication for preoperative chemotherapy (57 versus 33%, p = 0.0056) significantly differed when patients with single organ metastases experienced MDT discussion. CONCLUSIONS: MDT discussion is not as established as advocated by national guidelines. Treatment decisions differ especially in older patients and those with single organ metastases."],["dc.identifier.doi","10.1007/s00384-017-2871-z"],["dc.identifier.pmid","28779354"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14738"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59003"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","309"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical & Experimental Metastasis"],["dc.bibliographiccitation.lastpage","323"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Menck, Kerstin"],["dc.contributor.author","Schmick, Nadine Annette"],["dc.contributor.author","Schubert, Antonia"],["dc.contributor.author","Rietkoetter, Eva"],["dc.contributor.author","Arackal, Jetcy"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Schambony, Alexandra"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Klemm, Florian"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Pukrop, Tobias"],["dc.date.accessioned","2018-11-07T10:16:24Z"],["dc.date.available","2018-11-07T10:16:24Z"],["dc.date.issued","2016"],["dc.description.abstract","Liver metastasis development in breast cancer patients is common and confers a poor prognosis. So far, the prognostic significance of surgical resection and clinical relevance of biomarker analysis in metastatic tissue have barely been investigated. We previously demonstrated an impact of WNT signaling in breast cancer brain metastasis. This study aimed to investigate the value of established prognostic markers and WNT signaling components in liver metastases. Overall N = 34 breast cancer liver metastases (with matched primaries in 19/34 cases) were included in this retrospective study. Primaries and metastatic samples were analyzed for their expression of the estrogen (ER) and progesterone receptor, HER-2, Ki67, and various WNT signaling-components by immunohistochemistry. Furthermore, beta-catenin-dependent and -independent WNT scores were generated and analyzed for their prognostic value. Additionally, the influence of the alternative WNT receptor ROR on signaling and invasiveness was analyzed in vitro. ER positivity (HR 0.09, 95 % CI 0.01-0.56) and high Ki67 (HR 3.68, 95 % CI 1.12-12.06) in the primaries had prognostic impact. However, only Ki67 remained prognostic in the metastatic tissue (HR 2.46, 95 % CI 1.11-5.44). Additionally, the beta-catenin-independent WNT score correlated with reduced overall survival only in the metastasized situation (HR 2.19, 95 % CI 1.02-4.69, p = 0.0391). This is in line with the in vitro results of the alternative WNT receptors ROR1 and ROR2, which foster invasion. In breast cancer, the value of prognostic markers established in primary tumors cannot directly be translated to metastases. Our results revealed beta-catenin-independent WNT signaling to be associated with poor prognosis in patients with breast cancer liver metastasis."],["dc.identifier.doi","10.1007/s10585-016-9780-3"],["dc.identifier.isi","000373005900002"],["dc.identifier.pmid","26862065"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13177"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41033"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-7276"],["dc.relation.issn","0262-0898"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","beta-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1229"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer"],["dc.bibliographiccitation.lastpage","1237"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T10:28:34Z"],["dc.date.available","2018-11-07T10:28:34Z"],["dc.date.issued","2017"],["dc.description.abstract","The cellular sarcoma gene (SRC) is a proto-oncogene encoding for a tyrosine kinase. SRC expression was determined in locally advanced rectal adenocarcinoma tissue from pretreatment biopsies and resection specimens. The expression level was correlated with clinicopathological parameters to evaluate the predictive and prognostic capacity. For this monocentric analysis 186 patients with locally advanced rectal cancer (median: 63.7 years; 130 men (69.9%), 56 women (30.1%)) were included. Patients with a carcinoma of the upper third of the rectum were treated with primary tumor resection (n=27; 14.5%). All other patients received a preoperative chemoradiotherapy (CRT) with 50.4 Gy and concomitant 5-fluorouracil (5-FU) or 5-FU+oxaliplatin followed by postoperative chemotherapy with 5-FU or 5-FU+ oxaliplatin. SRC expression was determined with immunohistochemical staining from pretreatment biopsies (n=152) and residual tumor tissue from the resection specimens (n=163). The results were correlated with clinicopathological parameters and long-term follow-up. The expression of SRC was determined in pretherapeutic biopsies (mean H-Score: 229) and resection specimens (mean H-Score: 254). High SRC expression in pretherapeutic tumor samples significantly correlated with a negative postoperative nodal status (p=0.005). Furthermore an increased protein expression in residual tumor tissue was associated with fewer distant metastases (p=0.04). The overexpression of SRC in pretreatment tumor biopsies showed also a trend for a longer cancer-specific survival (CSS; p=0.05) and fewer local relapses (p=0.06) during long-term follow-up. High SRC expression in rectal cancer seems to be associated with a better long-term outcome. This finding could help in the future to stratify patients for a recurrence risk adapted postoperative treatment."],["dc.identifier.doi","10.7150/jca.16980"],["dc.identifier.isi","000402474000015"],["dc.identifier.pmid","28607598"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14945"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43450"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Ivyspring Int Publ"],["dc.relation.issn","1837-9664"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2442"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Surgical Oncology"],["dc.bibliographiccitation.lastpage","2452"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:52:40Z"],["dc.date.available","2018-11-07T08:52:40Z"],["dc.date.issued","2011"],["dc.description.abstract","For years, 5-fluorouracil (5-FU) has been the backbone of radiochemotherapy (RCT) of locally advanced rectal cancer. Its main target, thymidylate synthase (TS), is speculated to be an important biomarker for response prediction and long-term prognosis. In this study, we analyzed TS expression in the rectal cancer tissue of 208 patients to evaluate its predictive/prognostic potential. All patients included were diagnosed with locally advanced adenocarcinoma of the rectum (UICC II and III) and were treated within randomized clinical trials of the German Rectal Cancer Study Group. Preoperative RCT (50.4 Gy and concomitant either 5-FU or 5-FU and oxaliplatin) was administered in 167 patients followed by surgical resection with total mesorectal excision (TME). Another 41 patients received postoperative RCT. TS levels and further clinicopathological parameters were assessed in univariate and multivariate analyses. Additionally, a TS gene polymorphism was analyzed with respect to the intratumoral protein levels. Low TS expression in pretreatment biopsies correlated with impaired patient survival (p = 0.015). Analysis of a 28-bp repeat revealed a correlation between the 3/ 3 genotype and high TS expression in pretherapeutic biopsies. In this study, a correlation of TS expression and grade of RCT-induced tumor regression was not found. Histopathological examination confirmed a complete tumor remission in 16 patients (9.6%). Analyses of the resection specimen indicated an unfavorable prognosis for patients with low intratumoral TS expression in case of detected lymph node metastases (p = 0.04). TS can serve as a prognostic biomarker indicating an unfavorable prognosis for patients with low TS expression."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179]"],["dc.identifier.doi","10.1245/s10434-011-1608-4"],["dc.identifier.isi","000294346700008"],["dc.identifier.pmid","21347782"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7591"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22225"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1068-9265"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1359"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1367"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:05:22Z"],["dc.date.available","2018-11-07T09:05:22Z"],["dc.date.issued","2012"],["dc.description.abstract","Bilobar colorectal liver metastases (CRLM) are often considered incurable or associated with poor prognosis even after R0 resection. In this single-center study, we evaluate the impact of CRLM spreading on recurrence-free survival (RFS) and cancer-specific overall survival (CSS) after R0 resection of CRLM with respect to multimodal treatment strategies including perioperative chemotherapy and multistep resections. Between January 2001 and December 2010, R0 resection could be achieved in 70 patients with bilobar and 100 with unilobar CRLM. Extent of disease, perioperative chemotherapy, surgical procedures, adjuvant treatment, histopathological workup, RFS, and CSS were compared between both cohorts. Forty-six (66 %) patients with bilobar and 26 (26 %) patients with unilobar CRLM received preoperative chemotherapy (p < 0.001). For bilobar CRLM, more extended and multistep resection including portal vein occlusion were performed (29 % versus 3 %; p < 0.001). Morbidity (39 % versus 28 %, p = 0.183) and mortality (1 % versus 3 %, p = 0.644) rates were comparable in both patients' cohorts. Postoperative therapy was applied in adjuvant intent to 42 (60 %) versus 51 (51 %) patients (p = 0.275). The 5-year RFS and CSS rates were 24 % versus 31 % (p = 0.169) and 42 % versus 55 % (p = 0.131), respectively. To our single-center experience, there is no significant effect of CRLM spreading (bilobar versus unilobar) on RFS and CSS rates. Bilobar CRLM are more likely to require extended multimodal efforts to achieve R0 resection."],["dc.identifier.doi","10.1007/s00384-012-1455-1"],["dc.identifier.isi","000309171200014"],["dc.identifier.pmid","22430890"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25298"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1009"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1017"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:23:05Z"],["dc.date.available","2018-11-07T09:23:05Z"],["dc.date.issued","2013"],["dc.description.abstract","Surgery is the standard of care for resectable colorectal liver metastases (CRC-LM). Unfortunately, 60 % of patients develop secondary metastatic recurrence (SMR) after R0-resection of CRC-LM. We investigated the impact of surgical re-intervention and chemotherapy (Ctx) on survival in a consecutive series of patients with SMR. From 01/2001 to 11/2011, 104 out of 178 consecutive patients with R0-resection of CRC-LM developed SMR and were evaluated. The impact of surgical and Ctx re-interventions on recurrence free (RFS) and cancer-specific survival (CSS) was analyzed. Median follow-up was 28.0 (95 %CI: 19.4-37.4) months. SMR occurred in 81 patients at a single site (49x liver, 18x lung, 14x other) and in 23 patients at multiple sites. Forty-two patients were scheduled for primary surgery. Fifty-three patients were classified as non-resectable and treated with median 5.0 [IQR, 3.0-10.0] cycles of Ctx, combined with an EGFR/VEGF-antibody in 27 patients. Nine patients received best supportive care only. R0/R1 resection could be achieved in 35 patients primarily and even in 8 patients secondarily after Ctx. Surgical morbidity and mortality were 16 and 0 %, respectively. The 5-year RFS rates for patients with R0 versus R1-resection were 22 and 24 % (p = 0.948). The 5-year CSS rate for R0/R1-resected patients was 38 % versus 10 % for those patients treated by Ctx alone (p < 0.001). In SMR, surgical re-intervention is feasible and safe in a remarkable number of patients and offers significantly longer CSS compared to patients without resection."],["dc.identifier.doi","10.1007/s00384-013-1648-2"],["dc.identifier.isi","000321912200014"],["dc.identifier.pmid","23371333"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10297"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29498"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","96"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Gastrointestinal Surgery"],["dc.bibliographiccitation.lastpage","103"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:47:57Z"],["dc.date.available","2018-11-07T08:47:57Z"],["dc.date.issued","2010"],["dc.description.abstract","Preoperative chemoradiotherapy (CRT) is supposed not only to reduce lymph node metastases but also lymph node recovery in rectal cancer specimens. The objective of this prospective study was to determine the effects of chemoradiation on mesorectal lymph node retrieval under terms of a meticulous histopathological evaluation. Specimens from 64 consecutive patients with stage II/III rectal cancer receiving preoperative 5-FU-based CRT were investigated. All patients were treated within the German Rectal Cancer Trial CAO/ARO/AIO-04. After surgery (including quality assessed total mesorectal excision), extensive pathological diagnostics was performed with embedding and microscopic evaluation of the whole mesorectal soft tissue compartment. A total number of 2,021 lymph nodes were recovered (31.6 per specimen) within pathological work-up. There was no significant correlation between the number of retrieved nodes and patient- as well as tumor-dependent parameters. Lymph node size constantly amounted for less than 0.5 cm. Twenty patients (31.3%) had persistent nodal metastases. A considerable incidence of residual micrometastatic involvement in lymph nodes < 0.3 cm (in 9.4% of all patients) was detected by extensive pathologic work-up. Reliable nodal staging with high numbers of detected nodes was feasible after neoadjuvant CRT. Micrometastases frequently occur in small lymph nodes detected by microscopic evaluation."],["dc.identifier.doi","10.1007/s11605-009-1057-6"],["dc.identifier.isi","000272800000017"],["dc.identifier.pmid","19830503"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4050"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21083"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1091-255X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Preoperative Chemoradiotherapy Does Not Necessarily Reduce Lymph Node Retrieval in Rectal Cancer Specimens-Results from a Prospective Evaluation with Extensive Pathological Work-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","409"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","418"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Schuetze, Gunther"],["dc.contributor.author","Niessner, M."],["dc.contributor.author","Goralczyk, Armin Dietmar"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Langer, C."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Lorf, Thomas"],["dc.date.accessioned","2018-11-07T08:31:09Z"],["dc.date.available","2018-11-07T08:31:09Z"],["dc.date.issued","2009"],["dc.description.abstract","Patients with bilobular colorectal liver metastases (CRLM) experience poor prognosis, especially when curative resection cannot be achieved. However, resectability in these patients is often limited by low future remnant liver volume (FRLV). The latter can be enhanced by a two-stage liver resection, using portal vein ligation to induce liver hypertrophy. The aim of this prospective pilot study was to evaluate safety, secondary resectability, and time to recurrence of two-stage hepatectomy with portal vein ligation (PVL) and complete surgical clearance of the FRLV in patients with bilobular CRLM. Out of 24 patients (63 +/- 8.26 years) with extended bilobular CRLM (metachronous n = 10, synchronous n = 14), 18 received preoperative 5-FU-based chemotherapy combined with oxaliplatin or irinotecan. Staging included thoracoabdominal computed tomography and (18)F-fluorodeoxyglucose-positron emission tomography scans. First-stage procedure consisted of PVL, resection of all CRLM in the FRLV, and radiofrequency ablation (RFA) of CRLM situated near the future resection plane. During first-stage procedure, 7x RFA, 4x non-anatomical resections, and 4x bisegmentectomies were performed additionally to PVL. FRLV/body-weight ratio increased from 0.4% to 0.6% within 55 days (median) after PVL. Second-stage hepatectomy was performed in 19 patients without tumor progression. R0 resection was possible in 14 patients. During a median follow-up of 17 months, intrahepatic recurrence occurred in two, and extrahepatic recurrence in nine out of 14 patients. Two-stage hepatectomy with PVL and complete surgical clearance of FRLV is safe even after intensified systemic chemotherapy resulting in a curative resection rate of 58.3% (73.7% of re-explored cases)."],["dc.description.sponsorship","German Research Society (DFG)"],["dc.identifier.doi","10.1007/s00384-008-0620-z"],["dc.identifier.isi","000263683500007"],["dc.identifier.pmid","19084973"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3515"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17054"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Two-stage hepatectomy (R0) with portal vein ligation-towards curing patients with extended bilobular colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]